Łuksza, Marta
Sethna, Zachary M.
Rojas, Luis A.
Lihm, Jayon http://orcid.org/0000-0002-1308-6507
Bravi, Barbara http://orcid.org/0000-0003-4860-7584
Elhanati, Yuval
Soares, Kevin http://orcid.org/0000-0002-0406-017X
Amisaki, Masataka http://orcid.org/0000-0003-4153-4036
Dobrin, Anton
Hoyos, David
Guasp, Pablo http://orcid.org/0000-0002-3655-916X
Zebboudj, Abderezak http://orcid.org/0000-0002-4708-5211
Yu, Rebecca
Chandra, Adrienne Kaya
Waters, Theresa
Odgerel, Zagaa
Leung, Joanne
Kappagantula, Rajya
Makohon-Moore, Alvin http://orcid.org/0000-0002-4781-3565
Johns, Amber
Gill, Anthony
Gigoux, Mathieu http://orcid.org/0000-0002-1831-7597
Wolchok, Jedd http://orcid.org/0000-0001-6718-2222
Merghoub, Taha http://orcid.org/0000-0002-1518-5111
Sadelain, Michel http://orcid.org/0000-0002-9031-8025
Patterson, Erin
Monasson, Remi
Mora, Thierry
Walczak, Aleksandra M.
Cocco, Simona http://orcid.org/0000-0002-1852-7789
Iacobuzio-Donahue, Christine http://orcid.org/0000-0002-4672-3023
Greenbaum, Benjamin D. http://orcid.org/0000-0001-6153-8793
Balachandran, Vinod P. http://orcid.org/0000-0002-2956-223X
Article History
Received: 11 June 2021
Accepted: 7 April 2022
First Online: 19 May 2022
Competing interests
: L.A.R. is listed as an inventor of a patent related to oncolytic viral therapy (US20170051022A1). L.A.R., Z.M.S. and V.P.B. are listed as inventors on a patent application related to work on antigen cross-reactivity. M.Ł., B.D.G. and V.P.B. are listed as inventors on a patent application related to work on neoantigen quality modelling (63/303,500). C.I.-D. has received research support from Bristol-Myers Squibb. B.D.G. has received honoraria for speaking engagements from Merck, Bristol-Meyers Squibb and Chugai Pharmaceuticals; has received research funding from Bristol-Meyers Squibb; and has been a compensated consultant for PMV Pharma and Rome Therapeutics of which he is a co-founder. V.P.B. has received research support from Bristol-Myers Squibb and Genentech. J.W. is a consultant for Adaptive Biotech, Amgen, Apricity, Ascentage Pharma, Arsenal IO, Astellas, AstraZeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly, Elucida, F Star, Georgiamune, Imvaq, Kyowa Hakko Kirin, Linneaus, Merck, Neon Therapeutics, Polynoma, Psioxus, Recepta, Takara Bio, Trieza, Truvax, Sellas, Serametrix, Surface Oncology, Syndax, Syntalogic and Werewolf Therapeutics. J.W. receives grant/research support from Bristol Myers Squibb and Sephora. J.W. has equity in Tizona Pharmaceuticals, Adaptive Biotechnologies, Imvaq, Beigene, Linneaus, Apricity, Arsenal IO and Georgiamune. T. Merghoub is a co-founder and holds equity in IMVAQ Therapeutics; he is a consultant for Immunos Therapeutics, ImmunoGenesis and Pfizer; he has research support from Bristol-Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals, Peregrine Pharmaceuticals, Adaptive Biotechnologies, Leap Therapeutics and Aprea; he has patents on applications related to work on oncolytic viral therapy, alphavirus-based vaccine, neoantigen modelling, CD40, GITR, OX40, PD-1 and CTLA-4. The other authors declare no competing interests.